Laboratorios Farmaceuticos Rovi, S.A. (FRA:41L)

Market Cap	2.96B +12.1%
Revenue (ttm)	741.09M -3.4%
Net Income	131.82M -5.9%
EPS	2.58
Shares Out	n/a
PE Ratio	22.45
Forward PE	20.52
Dividend	0.78 (1.30%)
Ex-Dividend Date	Jul 13, 2026

Volume	n/a
Open	57.60
Previous Close	58.20
Day's Range	57.60 - 57.70
52-Week Range	52.30 - 85.65
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 6, 2026

About FRA:41L

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Expr...

• Industry: Pharmaceutical Preparations
• Founded: 1946
• Employees: 1,998
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 41L

Financial Performance

In 2025, FRA:41L's revenue was 743.48 million, a decrease of -2.65% compared to the previous year's 763.75 million. Earnings were 140.44 million, an increase of 2.60%.